Poverty and isolation are associated with worse pulmonary hypertension outcomes

PHA Canada
Apr 28, 2025
1 min read

A 2024 study looked at the association between socioeconomic disadvantage and pulmonary hypertension. In one New York hospital system, they found that patients with PH and socioeconomic disadvantage were more likely to die, even after accounting for other conditions the patients might have.

The authors suggest that improving social support, health care access, and health care affordability might reduce treatment barriers and improve outcomes. They also suggest that clinical trials include more people from underrepresented populations.

Read the CHEST 2024 conference abstract

Recent Posts

Promising results for drug candidate CS1

This press release reports that over the 12 months of their Expanded Access Program enrolling ten patients, the majority of patients with pulmonary arterial hypertension who completed treatment with d

Using sotatercept off-label in children

Clinical trials for sotatercept didn't include children, so any pediatric use is off-label. This study, conducted at one children's hospital in San Diego, evaluated sotatercept in 7 pediatric patients

Phase 1 trial of treprostinil prodrug patch succeeds

A 9-participant phase 1 clinical trial used a patch to deliver a prodrug of treprostinil (a prodrug is something that is metabolized into the drug in question inside the body). Each participant wore a

Comments